DK2105164T3 - Nye P2X7R-antagonister og deres anvendelse - Google Patents
Nye P2X7R-antagonister og deres anvendelseInfo
- Publication number
- DK2105164T3 DK2105164T3 DK09004301.9T DK09004301T DK2105164T3 DK 2105164 T3 DK2105164 T3 DK 2105164T3 DK 09004301 T DK09004301 T DK 09004301T DK 2105164 T3 DK2105164 T3 DK 2105164T3
- Authority
- DK
- Denmark
- Prior art keywords
- new
- p2x7r
- antagonists
- p2x7r antagonists
- carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08005532 | 2008-03-25 | ||
US4105008P | 2008-03-31 | 2008-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2105164T3 true DK2105164T3 (da) | 2011-03-21 |
Family
ID=41010874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09004301.9T DK2105164T3 (da) | 2008-03-25 | 2009-03-25 | Nye P2X7R-antagonister og deres anvendelse |
Country Status (18)
Country | Link |
---|---|
US (2) | US8232290B2 (fr) |
EP (1) | EP2105164B1 (fr) |
JP (1) | JP5506776B2 (fr) |
CN (1) | CN102046240B (fr) |
AT (1) | ATE494926T1 (fr) |
AU (1) | AU2009228649B2 (fr) |
BR (1) | BRPI0910034B1 (fr) |
CA (1) | CA2719745C (fr) |
DE (1) | DE602009000550D1 (fr) |
DK (1) | DK2105164T3 (fr) |
EA (1) | EA022505B1 (fr) |
ES (1) | ES2357682T3 (fr) |
IL (1) | IL207976A0 (fr) |
NZ (1) | NZ587799A (fr) |
PL (1) | PL2105164T3 (fr) |
PT (1) | PT2105164E (fr) |
WO (1) | WO2009118175A1 (fr) |
ZA (1) | ZA201006782B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815892B2 (en) * | 2008-03-25 | 2014-08-26 | Affectis Pharmaceuticals Ag | P2X7R antagonists and their use |
WO2010075449A1 (fr) | 2008-12-24 | 2010-07-01 | Quest Diagnostics Investments Incorporated | Analyse par spectrométrie de masse pour l'hyperplasie surrénale congénitale |
CN102395562A (zh) * | 2009-04-14 | 2012-03-28 | 阿费克蒂斯制药股份公司 | 新的p2x7r拮抗剂及其用途 |
WO2012110190A1 (fr) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Nouveaux antagonistes p2x7r et leur utilisation |
WO2012163792A1 (fr) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Nouveaux antagonistes de p2x7r et leur utilisation |
WO2012163456A1 (fr) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Nouveaux antagonistes de p2x7r et leur utilisation |
BR112014001454A2 (pt) | 2011-07-22 | 2017-06-27 | Actelion Pharmaceuticals Ltd | derivados de amidas heterocíclicas como antagonistas do receptor de p2x7 |
JP6111268B2 (ja) * | 2012-01-20 | 2017-04-05 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | P2x7受容体アンタゴニストとしての複素環アミド誘導体 |
EP2931717B1 (fr) | 2012-12-12 | 2016-12-07 | Actelion Pharmaceuticals Ltd. | Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7 |
US9556117B2 (en) | 2012-12-18 | 2017-01-31 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as P2X7 receptor antagonists |
EP2956457B1 (fr) | 2013-01-22 | 2016-11-23 | Actelion Pharmaceuticals Ltd | Dérivés d'amides hétérocycliques utilisés comme antagonistes du récepteur p2x7 |
EP2956135B1 (fr) | 2013-01-22 | 2016-11-16 | Actelion Pharmaceuticals Ltd. | Dérivés d'amides hétérocycliques utilisés comme antagonistes du récepteur p2x7 |
US10071167B2 (en) | 2013-05-08 | 2018-09-11 | Children's Medical Center Corporation | Method of preventing and treating type 1 diabetes, allograft rejection and lung fibrosis (by targeting the ATP/P2X7R axis) |
WO2016100281A1 (fr) * | 2014-12-15 | 2016-06-23 | Merck Patent Gmbh | Dérivés indoliques et azaindoliques et leur utilisation dans le traitement de maladies neurodégénératives |
CN109879790B (zh) * | 2017-12-06 | 2022-09-20 | 华东师范大学 | 以吲哚或吲哚类似物为母核结构的酰胺类小分子有机化合物、用途及其制备方法 |
CN110668992B (zh) * | 2018-07-02 | 2023-06-09 | 华东师范大学 | Ido/hdac双靶点化合物及其合成方法和应用 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3705175A (en) * | 1969-04-01 | 1972-12-05 | Egyt Gyogyszervegyeszeti Gyar | Indazole-3-carboxylic amides |
WO1998038179A1 (fr) | 1997-02-26 | 1998-09-03 | Glaxo Group Limited | Derives d'hydroxamate utilises comme inhibiteurs de metalloprotease |
ZA988967B (en) | 1997-10-03 | 2000-04-03 | Du Pont Pharm Co | Lactam metalloprotease inhibitors. |
SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
EP1087937A1 (fr) | 1998-06-17 | 2001-04-04 | Du Pont Pharmaceuticals Company | Acides hydroxamiques cycliques utilises en tant qu'inhibiteurs de metalloproteases |
US6239151B1 (en) | 1998-06-26 | 2001-05-29 | Hoffmann-La Roche Inc. | Compounds as inhibitor of tumor necrosis factor alpha release |
UA59453C2 (uk) | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ |
US20040122011A1 (en) | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
BR0009651A (pt) | 1999-04-09 | 2002-01-08 | Astrazeneca Ab | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas |
SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
JP2004502642A (ja) * | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
EP1314721A1 (fr) | 2000-08-31 | 2003-05-28 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives d'acide propenohydroxamique |
WO2002096426A1 (fr) | 2001-05-25 | 2002-12-05 | Bristol-Myers Squibb Company | Derives d'hydantoine utilises comme inhibiteurs des metalloproteinases matricielles |
FR2825926A1 (fr) * | 2001-06-14 | 2002-12-20 | Sod Conseils Rech Applic | Derives d'imidazoles modulant les canaux sodiques |
WO2003016248A2 (fr) | 2001-08-17 | 2003-02-27 | Bristol-Myers Squibb Company Patent Department | Hydroxamates bicycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou enzyme de conversion du tnf-$g(a) (tace) |
WO2003024899A2 (fr) | 2001-09-17 | 2003-03-27 | Bristol-Myers Squibb Company | Acides hydroxamiques cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace) |
WO2003031431A1 (fr) | 2001-10-09 | 2003-04-17 | Bristol-Myers Squibb Company | Derives de sulfone cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace) |
AU2002365132A1 (en) | 2001-10-17 | 2003-07-15 | Bristol-Myers Squibb Company | BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-Alpha CONVERTING ENZYME (TACE) |
US20030212056A1 (en) | 2001-11-02 | 2003-11-13 | Jingwu Duan | Beta-sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
WO2003042190A1 (fr) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | Derives de n-adamantylalkyle benzamide en tant qu'antagonistes du recepteur p2x7 |
PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
AU2002359524A1 (en) | 2001-11-30 | 2003-06-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health A | P2x7 receptor antagonists |
AU2002357312A1 (en) | 2001-12-20 | 2003-07-09 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases |
NZ533649A (en) | 2001-12-21 | 2006-01-27 | King Pharmaceuticals Res & Dev | Tyrosyl derivatives and their use as P2X7 receptor modulators |
WO2003079986A2 (fr) | 2002-03-18 | 2003-10-02 | Bristol-Myers Squibb Company | Derives d'uracile utilises en tant qu'inhibiteurs de l'enzyme tnf-alpha convertase (tace) et metalloproteases matricielles |
SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
UA77303C2 (en) * | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
GB0216379D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Compounds |
WO2004012663A2 (fr) | 2002-08-01 | 2004-02-12 | Bristol-Myers Squibb Company | Derives d'yhydantoine utilises comme inhibiteurs de metalloproteases maticielles et/ou d'enzyme de conversion de tnf-alpha |
EP1546109A4 (fr) | 2002-10-04 | 2005-11-09 | Bristol Myers Squibb Co | Derives d'hydantoine en tant qu'inhibiteurs de metalloproteinases matricielles et/ou de l'enzyme de conversion de tnf-alpha (tace) |
EP1558581A4 (fr) | 2002-10-07 | 2007-07-25 | Bristol Myers Squibb Co | Derives de la triazolone et de la triazolethione |
WO2004043349A2 (fr) | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Derives d'isoxazoline comme inhibiteurs de metalloproteases matricielles et/ou d'enzyme de conversion de tnf-$g(a) |
AU2003288640A1 (en) | 2002-12-31 | 2004-07-22 | Pfizer Products Inc. | Benzamide inhibitors of the p2x7 receptor |
PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
ITMI20030287A1 (it) * | 2003-02-18 | 2004-08-19 | Acraf | Indazolammidi dotate di attivita' analgesica metodo, per |
SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
JP4731468B2 (ja) | 2003-05-12 | 2011-07-27 | ファイザー・プロダクツ・インク | P2x7受容体のベンズアミド阻害剤 |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
US7132432B2 (en) | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
GB0324498D0 (en) | 2003-07-21 | 2003-11-26 | Aventis Pharma Inc | Heterocyclic compounds as P2X7 ion channel blockers |
SE0302139D0 (sv) | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
SE0302192D0 (sv) | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
WO2005019182A1 (fr) | 2003-08-20 | 2005-03-03 | Bayer Healthcare Ag | Derives de pyrazolylmethylbenzamide utilises comme antagonistes du recepteur p2xt |
JP2007509180A (ja) | 2003-10-21 | 2007-04-12 | インスパイアー ファーマシューティカルズ,インコーポレイティド | 疼痛を治療するための、非ヌクレオチド組成物および方法 |
WO2005111003A1 (fr) | 2004-04-29 | 2005-11-24 | Abbott Laboratories | Analogues d’amino-tétrazoles et méthodes d’utilisation |
AU2005258911A1 (en) | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H`1,2,4!triazin-2-YL!-benzamide derivatives by deprotecting the hydroxyl-protected precursers |
WO2006003513A1 (fr) | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Procede de preparation de derives de 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4-triazin-2-yl-benzamide aant une activite inhibant p2x7 par reaction du derive non substitue en position 4 de triazine avec un oxyrane en presence d'un acide de lewis |
US7241776B2 (en) | 2004-08-02 | 2007-07-10 | Abbott Laboratories | Cyanoamidine P2X7 antagonists for the treatment of pain |
SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
SE0402925D0 (sv) | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
NZ555768A (en) | 2004-12-24 | 2009-12-24 | Astrazeneca Ab | Benzamide derivatives as inhibitors of cytokine mediated disease |
JP2008528580A (ja) | 2005-01-27 | 2008-07-31 | アストラゼネカ・アクチエボラーグ | P2x7受容体の阻害剤である新規二環式芳香族化合物 |
US20060211739A1 (en) | 2005-02-08 | 2006-09-21 | Arturo Perez-Medrano | Use of selective P2X7 receptor antagonists |
US7297700B2 (en) | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
WO2006110516A1 (fr) | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Antagonistes de l'acylhydrazide p2x7 et leurs utilisations |
EP1885376A1 (fr) | 2005-05-05 | 2008-02-13 | Medicure International Inc. | Inhibition des voies dependantes de p2x7 mediees par l'atp au moyen de pyridoxal-5-phosphate et de composes associes a la vitamine b6 |
WO2007016597A2 (fr) | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Ciblage de secretion de facteur de croissance dependant d'enzyme de conversion de tnf-alpha (tace) dans une therapie anticancereuse |
US20090124555A1 (en) | 2005-08-29 | 2009-05-14 | Irma Bernatchez-Lemaire | Use of histogranin and histogranin-like compounds as inhibitors of p2x7 receptor function and as anti-arthritic agents |
US20100022531A1 (en) | 2005-09-01 | 2010-01-28 | Renovis, Inc. | Novel compounds as p2x7 modulators and uses thereof |
JP2009514864A (ja) | 2005-11-07 | 2009-04-09 | アボット・ラボラトリーズ | P2x7受容体拮抗薬および使用方法 |
CA2628260A1 (fr) | 2005-11-09 | 2007-05-18 | Abbott Laboratories | Antagonistes des recepteurs p2x7 et utilisations associees |
TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為p2x7調節劑之雙環雜芳基化合物與其用途 |
EP1937643B1 (fr) | 2006-03-16 | 2016-07-13 | Second Genome, Inc. | Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations |
CA2645652A1 (fr) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Composes de bicycloheteroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations |
DK2001474T3 (en) | 2006-03-16 | 2016-05-09 | Second Genome Inc | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND APPLICATIONS THEREOF |
WO2007109201A2 (fr) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations |
WO2007109182A2 (fr) | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations |
US20090149524A1 (en) | 2006-06-06 | 2009-06-11 | Paul John Beswick | N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration |
GB0611154D0 (en) | 2006-06-06 | 2006-07-19 | Glaxo Group Ltd | Novel receptor antagonists and their methods of use |
US20080076924A1 (en) | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
EA016076B1 (ru) | 2006-07-06 | 2012-01-30 | Глэксо Груп Лимитед | Замещенные n-фенилметил-5-оксопролин-2-амиды в качестве антагонистов р2х7-рецептора и способы их применения |
CA2714573A1 (fr) * | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Derives d'indazole |
CN102395562A (zh) * | 2009-04-14 | 2012-03-28 | 阿费克蒂斯制药股份公司 | 新的p2x7r拮抗剂及其用途 |
-
2009
- 2009-03-25 NZ NZ587799A patent/NZ587799A/en not_active IP Right Cessation
- 2009-03-25 WO PCT/EP2009/002189 patent/WO2009118175A1/fr active Application Filing
- 2009-03-25 BR BRPI0910034-2A patent/BRPI0910034B1/pt active IP Right Grant
- 2009-03-25 ES ES09004301T patent/ES2357682T3/es active Active
- 2009-03-25 EP EP09004301A patent/EP2105164B1/fr active Active
- 2009-03-25 US US12/411,090 patent/US8232290B2/en active Active
- 2009-03-25 CA CA2719745A patent/CA2719745C/fr active Active
- 2009-03-25 DE DE602009000550T patent/DE602009000550D1/de active Active
- 2009-03-25 AU AU2009228649A patent/AU2009228649B2/en active Active
- 2009-03-25 DK DK09004301.9T patent/DK2105164T3/da active
- 2009-03-25 PL PL09004301T patent/PL2105164T3/pl unknown
- 2009-03-25 CN CN200980120189.5A patent/CN102046240B/zh active Active
- 2009-03-25 EA EA201001522A patent/EA022505B1/ru not_active IP Right Cessation
- 2009-03-25 PT PT09004301T patent/PT2105164E/pt unknown
- 2009-03-25 AT AT09004301T patent/ATE494926T1/de active
- 2009-03-25 JP JP2011501146A patent/JP5506776B2/ja active Active
-
2010
- 2010-09-05 IL IL207976A patent/IL207976A0/en active IP Right Grant
- 2010-09-22 ZA ZA2010/06782A patent/ZA201006782B/en unknown
-
2012
- 2012-07-13 US US13/549,077 patent/US8569334B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PT2105164E (pt) | 2011-03-24 |
JP5506776B2 (ja) | 2014-05-28 |
NZ587799A (en) | 2012-06-29 |
JP2011515432A (ja) | 2011-05-19 |
PL2105164T3 (pl) | 2011-05-31 |
US20090312366A1 (en) | 2009-12-17 |
CN102046240A (zh) | 2011-05-04 |
CA2719745A1 (fr) | 2009-10-01 |
CN102046240B (zh) | 2014-06-25 |
WO2009118175A1 (fr) | 2009-10-01 |
CA2719745C (fr) | 2016-07-05 |
ZA201006782B (en) | 2011-05-25 |
ES2357682T3 (es) | 2011-04-28 |
US8232290B2 (en) | 2012-07-31 |
US20120302597A1 (en) | 2012-11-29 |
EA022505B1 (ru) | 2016-01-29 |
AU2009228649B2 (en) | 2014-05-22 |
EP2105164B1 (fr) | 2011-01-12 |
BRPI0910034A2 (pt) | 2021-03-30 |
AU2009228649A1 (en) | 2009-10-01 |
ATE494926T1 (de) | 2011-01-15 |
IL207976A0 (en) | 2010-12-30 |
BRPI0910034B1 (pt) | 2022-02-08 |
EP2105164A1 (fr) | 2009-09-30 |
DE602009000550D1 (de) | 2011-02-24 |
US8569334B2 (en) | 2013-10-29 |
EA201001522A1 (ru) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2105164T3 (da) | Nye P2X7R-antagonister og deres anvendelse | |
DK2243772T3 (da) | Hidtil ukendte P2X7R-antagonister og deres anvendelse | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
EA201100311A1 (ru) | Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы | |
MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
NO20083214L (no) | Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer | |
MX2013013692A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de beta secretasa 1 (bace1) y/o beta secretasa 2 (bace2). | |
EA201300669A1 (ru) | Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение | |
EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
MX2013007957A (es) | 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2). | |
NO20084328L (no) | Nye forbindelser | |
PH12015502365A1 (en) | Bace1 inhibitors | |
MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
MX2010004876A (es) | Derivados de diamido tiazol como inhibidores de la proteina cinasa. | |
PH12014502623A1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
ATE481972T1 (de) | Chinazolinon-derivate als vanilloid-antagonisten | |
ATE524463T1 (de) | 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung | |
MX2013002398A (es) | Inhibidores de beta-secretasa (base) para su uso en tratamiento de diabetes. | |
NO20082459L (no) | Nye prosesser for fremstilling av piperazinyl og diazapanylbenzamidderivater | |
EA201190003A1 (ru) | Производные хроменона в качестве trpv3 антагонистов | |
EA201391155A1 (ru) | Ингибитор катепсина с | |
MX2012001797A (es) | Inhibidores de catepsina c. |